| Ms Michelle Deanne Rice, CNM | |
|
921 Greeley St S, Stillwater, MN 55082-5935 | |
| (651) 439-1234 | |
| Not Available |
| Full Name | Ms Michelle Deanne Rice |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 921 Greeley St S, Stillwater, Minnesota |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659622322 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 246 (Minnesota) | Primary |
| Entity Name | Group Health Plan Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710924683 PECOS PAC ID: 1759293954 Enrollment ID: O20031223000493 |
News Archive
In this post in LA Progressive, Georgianne Nienaber, an investigative and political writer, examines the potential effects of reduced PEPFAR funding and highlights the non-denominational Christian ACTS clinic operating in South Africa as an example of a U.S. foreign aid success story.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.
The American Heart Association/American Stroke Association has proposed metrics that healthcare professionals can use to monitor the diagnosis and treatment of patients at stroke centers to help improve the quality of care stroke patients receive.
Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange announced today that it has commenced patient enrolment in a phase 2/3 clinical trial of CF101 for the treatment of Psoriasis.
A modeling study by Dr. Peter Ellis from the University of Kent indicates that ABO incompatibility between infected patients and susceptible individuals may actually decrease the transmissibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by 60% or more. His detailed investigation of such "ABO-interference" can be found on the medRxiv preprint server.
› Verified 2 days ago
| Entity Name | Ladd Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467560227 PECOS PAC ID: 9931092848 Enrollment ID: O20040204000998 |
News Archive
In this post in LA Progressive, Georgianne Nienaber, an investigative and political writer, examines the potential effects of reduced PEPFAR funding and highlights the non-denominational Christian ACTS clinic operating in South Africa as an example of a U.S. foreign aid success story.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.
The American Heart Association/American Stroke Association has proposed metrics that healthcare professionals can use to monitor the diagnosis and treatment of patients at stroke centers to help improve the quality of care stroke patients receive.
Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange announced today that it has commenced patient enrolment in a phase 2/3 clinical trial of CF101 for the treatment of Psoriasis.
A modeling study by Dr. Peter Ellis from the University of Kent indicates that ABO incompatibility between infected patients and susceptible individuals may actually decrease the transmissibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by 60% or more. His detailed investigation of such "ABO-interference" can be found on the medRxiv preprint server.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Michelle Deanne Rice, CNM 8170 33rd Ave S # Ms 21110q, Minneapolis, MN 55425-4516 Ph: () - | Ms Michelle Deanne Rice, CNM 921 Greeley St S, Stillwater, MN 55082-5935 Ph: (651) 439-1234 |
News Archive
In this post in LA Progressive, Georgianne Nienaber, an investigative and political writer, examines the potential effects of reduced PEPFAR funding and highlights the non-denominational Christian ACTS clinic operating in South Africa as an example of a U.S. foreign aid success story.
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar (sorafenib) tablets in patients with locally advanced or metastatic radioactive iodine-refractory (RAI) differentiated thyroid cancer has met its primary endpoint of a statistically significant improvement of progression-free survival.
The American Heart Association/American Stroke Association has proposed metrics that healthcare professionals can use to monitor the diagnosis and treatment of patients at stroke centers to help improve the quality of care stroke patients receive.
Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, ophthalmic, and liver diseases, traded on the Tel Aviv Stock Exchange announced today that it has commenced patient enrolment in a phase 2/3 clinical trial of CF101 for the treatment of Psoriasis.
A modeling study by Dr. Peter Ellis from the University of Kent indicates that ABO incompatibility between infected patients and susceptible individuals may actually decrease the transmissibility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by 60% or more. His detailed investigation of such "ABO-interference" can be found on the medRxiv preprint server.
› Verified 2 days ago
Ms. Fern Marie Aspen, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 921 Greeley St S, Stillwater, MN 55082 Phone: 651-439-1234 Fax: 651-439-1547 | |
Ms. Melissa Hanner Frisvold, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 921 Greeley St S, Stillwater, MN 55082 Phone: 651-439-1234 Fax: 651-439-1547 | |
Heather Dejarnett, Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 5640 Memorial Ave N, Suite B, Stillwater, MN 55082 Phone: 651-430-1880 |